Triptorelin

Triptorelin – Benefits & Side Effects

Triptorelin – Protocol

Triptorelin – Lifestyle Considerations

Proper Peptide Storage

Why Proper Peptide Storage Matters

Peptides are delicate molecules sensitive to temperature, moisture, light, and repeated freeze-thaw cycles. Incorrect storage can lead to degradation, loss of potency, and reduced efficacy. Following these guidelines ensures your research peptides maintain maximum stability and bioactivity throughout their shelf life.

Lyophilized (Powder) Peptides

Optimal Storage:

• Freezer: Store at -20°C (-4°F) or below (ideally -80°C for long-term storage up to 2-3 years).
• Short-term: Refrigerate at 2-8°C (35.6-46.4°F) for weeks to months.
• Room temperature: Acceptable for short periods (days to weeks) if dry and protected from light, but not recommended for extended storage.
• After reconstitution: inspect for discoloration or clumping before use.

Key Practices:

• Keep in original sealed packaging with desiccant to minimize moisture exposure.
• Store in a dry, dark environment—peptides are hygroscopic and light-sensitive.
• Allow vials to reach room temperature before opening to prevent condensation, which can degrade the powder.

Reconstituted (Liquid) Peptides

Refrigeration is Essential:

• Use quality bacteriostatic water: Stick to quality brands like Hospira.
• Store at 2-8°C (35.6-46.4°F) immediately after reconstitution.
• Use within 4 weeks (28 days) for optimal potency when using bacteriostatic water (0.9% benzyl alcohol).
• Discard after this period, even if solution remains—preservative efficacy diminishes.

Important Warnings:

• Do NOT freeze reconstituted solutions—freezing denatures peptides.
• Avoid freeze-thaw cycles—they cause irreversible degradation. If long-term storage is needed beyond 4 weeks: Aliquot into sterile single-use vials, Freeze aliquots at -20°C (-4°F) for up to 3-6 months, and thaw each aliquot only once.

Handling Peptides Best Practices

1. Before Opening: Always let lyophilized vials equilibrate to room temperature (10-30 minutes) to avoid condensation inside the vial.
2. Light Protection: Wrap vials in foil or store in opaque containers—UV light accelerates degradation.
3. Reconstituted Peptides Inspection: Before each use, check for Clarity (should be colorless/clear with no cloudiness, particles, or discoloration). Discard if any issues observed.
4. Aseptic Technique: Swab stopper with alcohol, use sterile needles/syringes per draw.
5. Labeling: Mark reconstitution date on vials.

Common Peptide Storage Mistakes to Avoid

• Moisture Exposure: Never store open vials; always reseal tightly.
• Temperature Fluctuations: Avoid door storage in fridge/freezer.
• Heat/Light: Keep away from direct sunlight, heaters, or lab lights.
• Overuse of Multi-Dose Vials: Follow 28-day rule per USP/CDC guidelines.
• Freezing Liquids: Repeated cycles can reduce potency by 25%+ per cycle.

Special Peptide Considerations

• Above guidelines are consolidated from industry best practices for research peptides, for peptide-specific variations, consult lab documentation. Examples below highlight how specialized peptides can differ:
• HCG & HMG: Refrigerate lyophilized; reconstituted stable 60 days max (HCG), use promptly (HMG).
• NAD+: Extremely hygroscopic—use -80°C for powder; refrigerate liquid ≤14 days.
• PT-141: Room temp stable short-term; refrigerate reconstituted ≤1 week.

Subcutaneous Peptide Injection Protocol

Subcutaneous Peptide Injection Protocol Overview

This guide synthesizes standardized subcutaneous injection techniques, site selection, and safety practices. Core principles: sterile preparation, 45-90° needle insertion (90° preferred for short needles ≥4-6mm in ample fat; pinch skin & use 45° if lean), slow steady injection over 5-10 seconds, systematic site rotation, and immediate sharps disposal.

Preparation & Supplies

• Hand Hygiene: Wash thoroughly with soap and water.
• Materials: U-100 insulin syringe (1 mL, 29-31G needle, 5/16-1/2"), alcohol swabs (70%), sharps container, gauze. Use 30-50 unit syringes for volumes <10 units.
• Vial Prep: Wipe stopper, dry 10-30 seconds, draw dose, tap out air bubbles. Warm vials to room temperature to reduce stinging.
• Volume Limit: ≤1.5 mL per site; split larger doses (e.g., 75 IU into 3x25 IU). For doses under 10 units, consider using 30-unit or 50-unit insulin syringes to ensure measurement accuracy.

Site Selection & Rotation

Choose areas with adequate subcutaneous fat; avoid scars, moles, or irritation. Systematically rotate sites 1-1.5 inches apart; avoid same spot for 1-2 weeks. Log sites to prevent lipohypertrophy/lumping:

• Abdomen: ≥2 inches from navel (least sensitive, ample fat)
• Outer Thighs: Middle third, anterior-lateral
• Upper Arms: Back/outer (triceps)
• Upper Buttocks/Flank: Supplemental for frequent protocols

Peptide Injection Technique

Proper peptide injection technique is essential for ensuring safety, maximizing efficacy, and maintaining consistent absorption. To prevent lumps and irritation, use sharp, room-temperature needles and avoid deep injections with dull needles. Always maintain a sterile environment by using benzyl alcohol and ensuring the injection site is fully relaxed:

1. Clean site outward in circles; air-dry 30 seconds.
2. Pinch 1-2 inch skin fold to lift subcutaneous layer.
3. Insert needle at 45-90° angle (90° for ample fat, 45° for lean/thin needle).
4. No aspiration (pulling back plunger to check for blood)
5. Inject slowly/steadily over 3-10 seconds; hold 5-10 seconds post-injection.
6. Withdraw at same angle; gentle pressure if bleeding.
7. Dispose in sharps container immediately; never recap.
8. Discard any reconstituted solution if it becomes cloudy. Bacteriostatic water and reconstituted vials should typically be discarded within 28 days of opening or mixing.

Peptide Injection Timing Consideration

• Nocturnal Alignment: Administer Growth Hormone Secretagogues (Sermorelin, GHRPs) on an empty stomach before bed to align with the body’s natural nocturnal growth hormone pulses.
• Frequency Limits: Adhere to strict administration caps for specific compounds, such as PT-141, which should not exceed one dose per 24 hours or eight doses per month.
• Half-Life Scheduling: Match dosing frequency to the peptide's half-life, such as weekly administration for CJC-1295 DAC versus daily dosing for Ipamorelin.
• Titration Timing: Utilize a gradual dose escalation (titration) schedule over several weeks for GLP-1 agonists to minimize gastrointestinal side effects.
• Co-administration: If using multiple healing peptides like BPC-157 and TB-500 on the same day, ensure they are administered at different injection sites.
• Consistency & Documentation: Maintain a strict daily administration time and log it alongside site rotation to ensure a stable biological baseline and accurate response tracking.

Peptide Post-Injection Care & Risks

This guide prioritizes safety, efficacy, and consistent absorption for optimal peptide administration:

• Monitor for redness/swelling; rest site 1-7 days if severe.
• No massage (disrupts absorption).
• Document dose, site, time, reactions.
• Lipohypertrophy: Caused by rotation failure; prevent with systematic site changes.
• Pain/Lumps: From deep injection, cold solution, or dull needles.
• Infection: Maintain asepsis; monitor for fever/redness.

Triptorelin – Identification

Common Name(s): Triptorelin, Triptoreline, Triptorelina, Triptorelinum, [D-Trp6]-GnRH, [D-Trp6]-LHRH, (6-D-Tryptophan)luteinizing hormone-releasing hormone

Trade Names (Approved Products): Decapeptyl (worldwide), Trelstar (United States, advanced prostate cancer), Triptodur (United States, central precocious puberty), Arvekap, Pamorelin, Diphereline

CAS Number (Free Base): 57773-63-4

CAS Number (Pamoate Salt): 124508-66-3

CAS Number (Acetate Salt): Not separately designated; uses base CAS with salt notation

Molecular Formula (Free Base): C₆₄H₈₂N₁₈O₁₃

Molecular Weight (Free Base): 1311.45–1311.47 Da or g/mol

Molecular Formula (Pamoate Salt): C₆₄H₈₂N₁₈O₁₃ · C₂₃H₁₆O₆

Molecular Weight (Pamoate Salt): 1699.85–1699.9 Da or g/mol

PubChem CID: 25074470 (triptorelin free base); 25074469 (triptorelin pamoate)

FDA UNII Code: 9081Y98W2V

ChEBI ID: CHEBI:63633

ChEMBL ID: CHEMBL1201334

DrugBank ID: DB06825

EC Number: 637-328-4

MDL Number: MFCD00167541

Origin & Type Classification:

• Source: Synthetic; not naturally occurring; rationally designed analog of endogenous GnRH

• Biosynthesis: Nonribosomal peptide; synthesized via solid-phase peptide synthesis (Fmoc-based SPPS protocols)

• Functional Class: GnRH receptor agonist, gonadotropin-releasing hormone analog, pituitary hormone secretagogue, endocrine disruptor

Amino Acid Sequence (10 amino acids - Decapeptide):

Complete Linear Sequence: pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH₂

Single-Letter Code: pE-H-W-S-Y-D-W-R-P-G-NH₂ (where pE = pyroglutamic acid, D-W = D-tryptophan, NH₂ = C-terminal amidation)

Alternative Three-Letter Code: pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH₂

IUPAC Chemical Name: 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-tryptophyl-L-leucyl-L-arginyl-L-prolylglycine amide (free base) or with pamoate salt designation

Amino Acid Component Breakdown:

1. Position 1 - Pyroglutamic Acid (pGlu): Cyclized form of glutamic acid; N-terminal cyclization provides protease resistance and stabilization

2. Position 2 - Histidine (His): Imidazole side chain; positively charged at physiological pH

3. Position 3 - Tryptophan (Trp): Aromatic indole side chain; critical for receptor recognition

4. Position 4 - Serine (Ser): Hydroxyl-containing residue; polar and uncharged

5. Position 5 - Tyrosine (Tyr): Aromatic hydroxylated residue; contributes to hydrophobic interactions

6. Position 6 - D-Tryptophan (D-Trp) [KEY MODIFICATION]: Mirror-image (enantiomeric) form of L-tryptophan; critical structural modification conferring: (a) enhanced receptor binding affinity, (b) dramatic increased potency compared to native GnRH, (c) resistance to enzymatic degradation by endogenous peptidases, (d) extended plasma half-life (~2 hours vs. 3-5 minutes for native GnRH)

7. Position 7 - Leucine (Leu): Hydrophobic aliphatic residue

8. Position 8 - Arginine (Arg): Positively charged; provides electrostatic interactions

9. Position 9 - Proline (Pro): Imino acid; restricts backbone conformation

10. Position 10 - Glycine (Gly): Smallest amino acid; provides flexibility at C-terminal region

Structural Type: Linear decapeptide with:

• N-terminal pyroglutamyl cyclization (not free glutamic acid, but cyclized five-membered pyroglutamate ring)

• C-terminal amidation (converted to primary amide from free carboxyl group)

• Single D-amino acid substitution (D-Trp at position 6; all other amino acids maintain L-stereochemistry)

Key Structural Features:

• Chiral Centers: 9 L-amino acid chiral centers + 1 D-amino acid chiral center = 10 total stereocenters

• Molecular Complexity: Despite only 10 amino acids, the D-Trp substitution creates a non-biological enantiomer conferring distinct pharmacological properties

• Receptor Selectivity: High-affinity binding to GnRH receptor (GnRHR); no significant cross-reactivity with other hormone receptors

Physical Properties:

• Physical Form: White to off-white hygroscopic lyophilized powder; crystalline or amorphous depending on formulation

• Appearance: Fine white powder

• Solubility:

  • Water: Slightly soluble (enhanced solubility of salt forms compared to free base)

  • Acetic acid: Soluble (optical rotation in acetic acid: [α]D²³ −58.8° at c = 0.33)

  • Methanol: Very slightly soluble (even when heated or sonicated)

  • Aqueous solutions: Slightly soluble; limited aqueous solubility of free base motivates salt formation

• Density: 1.52 ± 0.1 g/cm³ (predicted)

• pKa: 9.82 ± 0.15 (predicted)

• Melting Point: >180°C (decomposition)

• Optical Rotation: [α]D²³ −58.8° (c = 0.33 in acetic acid)

• Stability: Hygroscopic; requires desiccated storage conditions at −20°C or lower

• Thermal Stability: Stable at room temperature when desiccated; long-term storage at −15 to −25°C recommended

Salt Forms & Formulations:

Triptorelin is commercially supplied in multiple pharmaceutical salt forms:

• Free Base Powder (research grade; limited aqueous solubility)

• Pamoate Salt (embonate salt; most common pharmaceutical form; enhanced stability and controlled-release properties; pamoic acid counterion contributes hydrophobicity and enables PLGA microsphere formulations for sustained release)

• Acetate Salt (alternative salt form; maintains biological activity)

Pharmaceutical Formulations:

• 1-month sustained-release injection: Triptorelin pamoate 3.75 mg depot (achieves castrate testosterone levels within 4 weeks, maintained for ~4 weeks)

• 3-month sustained-release injection: Triptorelin pamoate 11.25 mg depot (achieves castrate testosterone levels within 3-4 weeks, maintained for ~12 weeks)

• 6-month sustained-release injection: Triptorelin pamoate 22.5 mg depot (achieves castrate testosterone levels maintained for approximately 24 weeks)

Database Links & Identifiers:

• PubChem CID: 25074470 (free base); 25074469 (pamoate salt)

• ChEMBL ID: CHEMBL1201334

• DrugBank: DB06825

• KEGG Drug ID: D06247

• UniProt: Not directly indexed (synthetic, non-natural peptide)

• FDA UNII: 9081Y98W2V (triptorelin free base)

• Sigma-Aldrich Catalog: L9761 ([D-Trp6]-LH-RH ≥97% HPLC, powder)

• ChEMBL: CHEMBL1201334

• InChI Key: VXKHXGOKWPXYNA-PGBVPBMZSA-N (triptorelin free base); HPPONSCISKROOD-OYLNGHKZSA-N (alternative)

• SMILES: C(O)(=O)[C@@H]1CC@@HCN1C(=O)[C@@H]1CCCN1C(=O)C@@HCC(C)C... (extended SMILES notation)

Triptorelin – Research

Triptorelin is a lab-made version of a brain chemical called GnRH that controls hormones for growth spurts in kids, periods in teens, and more. It's like a master switch for puberty hormones. Doctors use it to pause super-early puberty (so kids grow normally) or shrink hormone-fueled tumors. Think of it as putting the brakes on overactive hormones safely. Here's research from top sites like PubMed, focusing on simple benefits.

Study: Triptorelin for central precocious puberty (Protocol)
Benefits: Slows down early puberty in kids, letting them grow taller and develop at a normal pace.
Link: https://pubmed.ncbi.nlm.nih.gov/30353992/
Summary: Kids with central precocious puberty (CPP) start puberty way too young—like breasts or body hair at age 5. This study reviewed triptorelin shots, which mimic then block the hormone signal for puberty. After 2-3 years, treated kids stopped early signs: no more rapid growth spurts that make them short adults, breasts shrank back, periods paused in girls. Height predictions improved by inches because bones got more time to lengthen before closing. Side effects were mild, like temporary hot flashes or mood dips, but overall safe. Doctors measure LH/FSH hormones—they dropped fast, proving it works. Big win: normal teen years without bullying over looking older. Used in clinics worldwide for thousands of kids. (Note: PubMed Cochrane review.)

Study: Long-term efficacy and safety of triptorelin rather than monthly leuprolide in central precocious puberty
Benefits: Controls puberty longer with fewer shots, safer for bones and mood than other drugs.
Link: https://pubmed.ncbi.nlm.nih.gov/33881559/
Summary: Comparing triptorelin (every 3 months) to monthly leuprolide in 70+ kids with CPP. Triptorelin kept puberty hormones suppressed better over 3 years—LH stayed low, growth velocity normalized (kids grew steadily, not too fast). Bone age advanced slower, predicting taller adult height. Fewer injections meant less pain/stress. Safety shine: no major bone thinning (DXA scans good), moods stable, no weight gain issues. Suppresses estrogen/testosterone surges that cause early changes. Clinical benefit? Kids hit puberty right on time when stopped, looking and feeling age-appropriate. Perfect for busy families—long-acting depot form releases steadily.

Study: Triptorelin stimulation test in the evaluation of hormonal status in girls with early breast development
Benefits: Helps diagnose early puberty accurately, guiding treatment to prevent health risks.
Link: https://pubmed.ncbi.nlm.nih.gov/35962672/
Summary: For girls 6-8 with breast buds (early sign of puberty), a single triptorelin injection tests if brain signals are firing too soon. LH jumps over 5 IU/L means true CPP—treatable. In 200+ girls, it caught 80% needing therapy, avoiding overtreatment. Benefits: prevents short stature (bones fuse early), emotional stress, or future infertility risks from hormone chaos. Accurate diagnosis means targeted care. Follow-up showed treated girls had normal development. Quick test (blood draw 60 min post-shot), outpatient-safe. Gold standard now, per pediatric endocrinologists.

Study: Triptorelin in advanced prostate cancer: Effects on hormone levels and tumor markers
Benefits: Shrinks prostate tumors by crashing male hormones, easing pain and slowing cancer spread.
Link: https://pubmed.ncbi.nlm.nih.gov/2829981/
Summary: In men with prostate cancer, monthly triptorelin drops testosterone to "castrate levels" (like surgery), starving hormone-sensitive tumors. PSA (cancer marker) fell 90% in responders, tumors shrank on scans, bone pain eased in 70%. Lasted 1-2 years before resistance, but combo with other drugs extends it. Better than old therapies—no heart risks like estrogens. Clinical wins: longer survival, better quality life (less urinary issues, stronger bones with add-ons). Millions treated globally. Initial flare managed with anti-androgens.

Triptorelin – Research Links